316 related articles for article (PubMed ID: 23580147)
1. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification.
Osako MK; Nakagami H; Shimamura M; Koriyama H; Nakagami F; Shimizu H; Miyake T; Yoshizumi M; Rakugi H; Morishita R
Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1287-96. PubMed ID: 23580147
[TBL] [Abstract][Full Text] [Related]
2. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
[TBL] [Abstract][Full Text] [Related]
3. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification.
Osako MK; Nakagami H; Koibuchi N; Shimizu H; Nakagami F; Koriyama H; Shimamura M; Miyake T; Rakugi H; Morishita R
Circ Res; 2010 Aug; 107(4):466-75. PubMed ID: 20595654
[TBL] [Abstract][Full Text] [Related]
4. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL.
Di Bartolo BA; Cartland SP; Harith HH; Bobryshev YV; Schoppet M; Kavurma MM
PLoS One; 2013; 8(9):e74211. PubMed ID: 24040204
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
Min LJ; Mogi M; Iwanami J; Li JM; Sakata A; Fujita T; Tsukuda K; Iwai M; Horiuchi M
Cardiovasc Res; 2007 Dec; 76(3):506-16. PubMed ID: 17706954
[TBL] [Abstract][Full Text] [Related]
6. Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6.
Callegari A; Coons ML; Ricks JL; Rosenfeld ME; Scatena M
J Vasc Res; 2014; 51(2):118-31. PubMed ID: 24642764
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors.
Lemarié CA; Simeone SM; Nikonova A; Ebrahimian T; Deschênes ME; Coffman TM; Paradis P; Schiffrin EL
Circ Res; 2009 Oct; 105(9):852-9. PubMed ID: 19762686
[TBL] [Abstract][Full Text] [Related]
8. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
D'Amelio P; Isaia G; Isaia GC
J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
[TBL] [Abstract][Full Text] [Related]
9. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification.
Carrillo-López N; Martínez-Arias L; Alonso-Montes C; Martín-Carro B; Martín-Vírgala J; Ruiz-Ortega M; Fernández-Martín JL; Dusso AS; Rodriguez-García M; Naves-Díaz M; Cannata-Andía JB; Panizo S
Nephrol Dial Transplant; 2021 Mar; 36(4):618-631. PubMed ID: 33367746
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
Ock S; Ahn J; Lee SH; Park H; Son JW; Oh JG; Yang DK; Lee WS; Kim HS; Rho J; Oh GT; Abel ED; Park WJ; Min JK; Kim J
Cardiovasc Res; 2012 Apr; 94(1):105-14. PubMed ID: 22298642
[TBL] [Abstract][Full Text] [Related]
11. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension.
Sendra J; Llorente-Cortés V; Costales P; Huesca-Gómez C; Badimon L
Cardiovasc Res; 2008 Jun; 78(3):581-9. PubMed ID: 18281370
[TBL] [Abstract][Full Text] [Related]
13. TLR2 Promotes Vascular Smooth Muscle Cell Chondrogenic Differentiation and Consequent Calcification via the Concerted Actions of Osteoprotegerin Suppression and IL-6-Mediated RANKL Induction.
Lee GL; Yeh CC; Wu JY; Lin HC; Wang YF; Kuo YY; Hsieh YT; Hsu YJ; Kuo CC
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):432-445. PubMed ID: 30626205
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells.
Esteban V; Ruperez M; Sánchez-López E; Rodríguez-Vita J; Lorenzo O; Demaegdt H; Vanderheyden P; Egido J; Ruiz-Ortega M
Circ Res; 2005 May; 96(9):965-73. PubMed ID: 15831814
[TBL] [Abstract][Full Text] [Related]
15. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy.
Ndip A; Williams A; Jude EB; Serracino-Inglott F; Richardson S; Smyth JV; Boulton AJ; Alexander MY
Diabetes; 2011 Aug; 60(8):2187-96. PubMed ID: 21659498
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification.
Callegari A; Coons ML; Ricks JL; Yang HL; Gross TS; Huber P; Rosenfeld ME; Scatena M
Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2491-500. PubMed ID: 23990207
[TBL] [Abstract][Full Text] [Related]
17. Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway.
Zhan JK; Tan P; Wang YJ; Wang Y; He JY; Tang ZY; Huang W; Liu YS
Cardiovasc Diabetol; 2014 Nov; 13():153. PubMed ID: 25407893
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells.
Min LJ; Mogi M; Li JM; Iwanami J; Iwai M; Horiuchi M
Circ Res; 2005 Sep; 97(5):434-42. PubMed ID: 16081869
[TBL] [Abstract][Full Text] [Related]
19. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
[TBL] [Abstract][Full Text] [Related]
20. Receptor activator of nuclear factor kappa B ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification.
Quercioli A; Luciano Viviani G; Dallegri F; Mach F; Montecucco F
Crit Pathw Cardiol; 2010 Dec; 9(4):227-30. PubMed ID: 21119343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
